Active ingredientEnarodustatCat. No. P-E043-001CAS 1262132-81-9Family · Pharmaceutical analytical standards
Enarodustat
An oral HIF prolyl hydroxylase inhibitor, approved in Japan in September 2020 for anaemia associated with chronic kidney disease. It stabilises HIF factors and so prompts the body to make more of its own erythropoietin. This family brings together the active ingredient and nitrosamines.
Did you know?It exploits the system by which cells sense oxygen, a discovery awarded the 2019 Nobel Prize to Semenza, Ratcliffe and Kaelin: it mimics the body's natural response to a lack of oxygen.
Go to the active ingredient →Active ingredientEnarodustatCat. No. P-E043-001CAS 1262132-81-9
NitrosamineN-Nitroso EnarodustatCat. No. P-E043-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.